Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Norvir

Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 10–11

Medicinal Product Interactions – Ritonavir with Protease Inhibitors Co-administered Dose of Co- Dose of Medicinal Product AUC Cmin Medicinal Product administered NORVIR Assessed Medicinal (mg) Product (mg) Atazanavir 300 q24h 100 q24h Atazanavir ↑ 86% ↑ 11 fold 1 Atazanavir ↑ 2 fold ↑ 3-7 fold Ritonavir increases the serum levels of atazanavir as a result of CYP3A4 inhibition. Clinical trials confirmed the safety and efficacy of 300 mg atazanavir once daily with ritonavir 100 mg once daily in treatment experienced patients. For further information, physicians should refer to the SmPC for atazanavir. Darunavir 600, single 100 q12h Darunavir ↑ 14 fold Ritonavir increases the serum levels of darunavir as a result of CYP3A inhibition. Darunavir must be given with ritonavir to ensure its therapeutic effect. Ritonavir doses higher than 100 mg twice daily have not been studied with darunavir. For further information, refer to the SmPC for darunavir. Fosamprenavir 700 q12h 100 q12h Amprenavir ↑ 2.4 ↑ 11 fold fold Ritonavir increases the serum levels of amprenavir (from fosamprenavir) as a result of CYP3A4 inhibition. Fosamprenavir must be given with ritonavir to ensure its therapeutic effect. Clinical trials confirmed the safety and efficacy of fosamprenavir 700 mg twice daily with ritonavir 100 mg twice daily. Ritonavir doses higher than 100 mg twice daily 10 have not been studied with fosamprenavir. For further information, physicians should refer to the SmPC for fosamprenavir. Indinavir 800 100 q12h Indinavir2 ↑ 178% ND q12h Ritonavir ↑ 72% ND Ritonavir increases the serum levels of indinavir as a result of CYP3A4 inhibition. Appropriate doses for this combination, with respect to efficacy and safety, have not been established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is achieved with doses higher than 100 mg twice daily. In cases of co-administration of ritonavir (100 mg twice daily) and indinavir (800 mg twice daily) caution is warranted as the risk of nephrolithiasis may be increased. Nelfinavir 1250 100 q12h Nelfinavir ↑ ND q12h 20to39% Ritonavir increases the serum levels of nelfinavir as a result of CYP3A4 inhibition. Appropriate doses for this combination, with respect to efficacy and safety, have not been established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is achieved with doses higher than 100 mg twice daily. Tipranavir 500 200 q12h Tipranavir ↑ 11 fold ↑ 29 fold q12h Ritonavir ↓ 40% ND Ritonavir increases the serum levels of tipranavir as a result of CYP3A inhibition. Tipranavir must be given with low dose ritonavir to ensure its therapeutic effect. Doses of ritonavir less than 200 mg twice daily should not be used with tipranavir as they might alter the efficacy of the combination. For further information, physicians should refer to the SmPC for tipranavir. ND: Not determined. 1. Based on cross-study comparison to 400 mg atazanavir once daily alone. 2. Based on cross-study comparison to 800 mg indinavir three times daily alone.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) atazanavir (HOS-086180) nelfinavir (HOS-084520) protease (HOS-085623) amprenavir (HOS-086183) darunavir (HOS-086181) fosamprenavir (HOS-086182) tipranavir (HOS-086184)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 03a194213ac89748c50cfb4b51554f8455df8df904ff2077009223828e61e82e · Zeichen 2655–7456 im Abschnitt

Wechselwirkungen · Norvir

Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 43

HOS-086399 · Präparat HOS-083284

Co- Dose of Co- Dose of Medicinal Product AUC Cmin administered administered NORVIR Assessed Medicinal Medicinal Product (mg) Product (mg) Atazanavir 300 q24h 100 q24h Atazanavir ↑ 86% ↑ 11 fold 1 Atazanavir ↑ 2 fold ↑ 3-7 fold Ritonavir increases the serum levels of atazanavir as a result of CYP3A4 inhibition. Clinical trials confirmed the safety and efficacy of 300 mg atazanavir once daily with ritonavir 100 mg once daily in treatment experienced patients. For further information, physicians should refer to the SmPC for atazanavir. Darunavir 600, single 100 q12h Darunavir ↑ 14 fold Ritonavir increases the serum levels of darunavir as a result of CYP3A inhibition. Darunavir must be given with ritonavir to ensure its therapeutic effect. Ritonavir doses higher than 100 mg twice daily have not been studied with darunavir. For further information, refer to the SmPC for darunavir. Fosamprenavir 700 q12h 100 q12h Amprenavir ↑ 2.4 ↑ 11 fold fold Ritonavir increases the serum levels of amprenavir (from fosamprenavir) as a result of CYP3A4 inhibition. Fosamprenavir must be given with ritonavir to ensure its therapeutic effect. Clinical trials confirmed the safety and efficacy of fosamprenavir 700 mg twice daily with ritonavir 100 mg twice daily. Ritonavir doses higher than 100 mg twice daily have not been studied with fosamprenavir. For further information, physicians should refer to the SmPC for fosamprenavir. Indinavir 800 q12h 100 q12h Indinavir2 ↑ 178% ND Ritonavir ↑ 72% ND Ritonavir increases the serum levels of indinavir as a result of CYP3A4 inhibition. Appropriate doses for this combination, with respect to efficacy and safety, have not been established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is achieved with doses higher than 100 mg twice daily. In cases of co-administration of ritonavir (100 mg twice daily) and indinavir (800 mg twice daily) caution is warranted as the risk of nephrolithiasis may be increased. Nelfinavir 1250 q12h 100 q12h Nelfinavir ↑ ND 20to39% Ritonavir increases the serum levels of nelfinavir as a result of CYP3A4 inhibition. Appropriate doses for this combination, with respect to efficacy and safety, have not been established. Minimal benefit of ritonavir-mediated pharmacokinetic enhancement is achieved with doses higher than 100 mg twice daily. Tipranavir 500 q12h 200 Tipranavir ↑ 11 fold ↑ 29 fold q12h Ritonavir ↓ 40% ND Ritonavir increases the serum levels of tipranavir as a result of CYP3A inhibition. Tipranavir must be given with low dose ritonavir to ensure its therapeutic effect. Doses of ritonavir less than 200 mg twice daily should not be used with tipranavir as they might alter the efficacy of the combination. For further information, physicians should refer to the SmPC for tipranavir. ND: Not determined.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) atazanavir (HOS-086180) nelfinavir (HOS-084520) amprenavir (HOS-086183) darunavir (HOS-086181) fosamprenavir (HOS-086182) tipranavir (HOS-086184)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage d5308747ba178c6ebd0e34322c465d7122d5458d70aff134d17f324382a8fc16 · Zeichen 2732–7211 im Abschnitt

Wechselwirkungen · Viramune

Viramune 200 mg tablets · Abschnitt 4.5 · PDF-Seite 10

HOS-088096 · Präparat HOS-083615

Fosamprenavir Amprenavir AUC  0.67 It is not recommended to co- 1 400 mg BID (0.55-0.80) administer fosamprenavir and Amprenavir Cmin  0.65 Viramune if fosamprenavir is not (0.49-0.85) co-administered with ritonavir (see Amprenavir Cmax  0.75 section 4.4). (0.63-0.89)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amprenavir (HOS-086183) fosamprenavir (HOS-086182) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 4aa0db0ef4f3341ed440468fc01b765e9c7d5f0af16ee8980cfb5f148a9b0f43 · Zeichen 7414–7889 im Abschnitt

Wechselwirkungen · Viramune

Viramune 200 mg tablets · Abschnitt 4.5 · PDF-Seite 10–11

HOS-088098 · Präparat HOS-083615

10 Fosamprenavir/ritonavir Amprenavir AUC  0.89 Fosamprenavir/ritonavir and 700/100 mg BID (0.77-1.03) Viramune can be co-administered Amprenavir Cmin  0.81 without dose adjustments (0.69-0.96) Amprenavir Cmax  0.97 (0.85-1.10)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amprenavir (HOS-086183) fosamprenavir (HOS-086182) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage bfbfe45b93be9ebc394b0c89703ec2150b377802a50f01edc1848f3669c47163 · Zeichen 8135–8528 im Abschnitt

Wechselwirkungen · Viramune

Viramune 50 mg/5 mL oral suspension · Abschnitt 4.5 · PDF-Seite 35

HOS-088194 · Präparat HOS-083615

Fosamprenavir Amprenavir AUC  0.67 It is not recommended to co- 1 400 mg BID (0.55-0.80) administer fosamprenavir and Amprenavir Cmin  0.65 Viramune if fosamprenavir is not (0.49-0.85) co-administered with ritonavir (see Amprenavir Cmax  0.75 section 4.4). (0.63-0.89)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amprenavir (HOS-086183) fosamprenavir (HOS-086182) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 59ea8b49e42286e13a7691b99227f96872e505beb808469fa50ae61f3e922b7f · Zeichen 7648–8129 im Abschnitt

Wechselwirkungen · Viramune

Viramune 50 mg/5 mL oral suspension · Abschnitt 4.5 · PDF-Seite 35

HOS-088196 · Präparat HOS-083615

Fosamprenavir/ritonavir Amprenavir AUC  0.89 Fosamprenavir/ritonavir and 700/100 mg BID (0.77-1.03) Viramune can be co-administered Amprenavir Cmin  0.81 without dose adjustments (0.69-0.96) Amprenavir Cmax  0.97 (0.85-1.10)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amprenavir (HOS-086183) fosamprenavir (HOS-086182) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage dcefb192fd504181f1f7f7800988cdba35010eae61fe5df1e2b48750e4e05cad · Zeichen 8332–8718 im Abschnitt

Wechselwirkungen · Viramune

Viramune 400 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 60

HOS-088288 · Präparat HOS-083615

Fosamprenavir Amprenavir AUC  0.67 It is not recommended to co- 1 400 mg BID (0.55-0.80) administer fosamprenavir and Amprenavir Cmin  0.65 Viramune if fosamprenavir is not (0.49-0.85) co-administered with ritonavir (see Amprenavir Cmax  0.75 section 4.4). (0.63-0.89)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amprenavir (HOS-086183) fosamprenavir (HOS-086182) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 4aa0db0ef4f3341ed440468fc01b765e9c7d5f0af16ee8980cfb5f148a9b0f43 · Zeichen 7734–8209 im Abschnitt

Wechselwirkungen · Viramune

Viramune 400 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 60–61

HOS-088290 · Präparat HOS-083615

60 Fosamprenavir/ritonavir Amprenavir AUC  0.89 Fosamprenavir/ritonavir and 700/100 mg BID (0.77-1.03) Viramune can be co-administered Amprenavir Cmin  0.81 without dose adjustments (0.69-0.96) Amprenavir Cmax  0.97 (0.85-1.10)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amprenavir (HOS-086183) fosamprenavir (HOS-086182) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 60f84f87a6d621df1cb81c6e63ab92965edd2defc29d2327752934a5e86cc0c3 · Zeichen 8455–8848 im Abschnitt

Wechselwirkungen · Kaletra

Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 12

HOS-108852 · Präparat HOS-093083

(inhibition of CYP3A enzymes) HIV CCR5 – antagonist Maraviroc Maraviroc: The dose of maraviroc should be AUC: ↑ 295% decreased to 150 mg twice daily Cmax: ↑ 97% during co-administration with Due to CYP3A inhibition by Kaletra 400/100 mg twice daily. lopinavir/ritonavir. Integrase inhibitor Raltegravir Raltegravir: No dose adjustment necessary AUC: ↔ Cmax: ↔ C12: ↓ 30% Lopinavir: ↔ Co-administration with other HIV protease inhibitors (PIs) According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended. Fosamprenavir/ ritonavir Fosamprenavir: Co-administration of increased (700/100 mg BID) Amprenavir concentrations are doses of fosamprenavir (1400 mg significantly reduced. BID) with Kaletra oral solution (Lopinavir/ritonavir (533/133 mg BID) to protease 400/100 mg BID) inhibitor-experienced patients resulted in a higher incidence of or gastrointestinal adverse events and elevations in triglycerides with the Fosamprenavir (1400 mg combination regimen without BID) increases in virological efficacy, when compared with standard (Lopinavir/ritonavir doses of fosamprenavir/ritonavir. 533/133 mg BID) Concomitant administration of these medicinal products is not recommended. Tipranavir/ritonavir Lopinavir: Concomitant administration of (500/100 mg BID) AUC: ↓ 55% these medicinal products is not Cmin: ↓ 70% recommended. Cmax: ↓ 47% Acid reducing agents Omeprazole (40 mg QD) Omeprazole: ↔ No dose adjustment necessary

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) maraviroc (HOS-086186) amprenavir (HOS-086183) raltegravir (HOS-086187) fosamprenavir (HOS-086182) tipranavir (HOS-086184) omeprazole (HOS-085912)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 0b87fdd109f79a80601e3c574f5e18fed07b1789a2ca7f01d2eafaba29d23dc3 · Zeichen 4995–7833 im Abschnitt

Wechselwirkungen · Kaletra

Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 48

HOS-109004 · Präparat HOS-093083

(inhibition of CYP3A enzymes) HIV CCR5 – antagonist Maraviroc Maraviroc: The dose of maraviroc should be AUC: ↑ 295% decreased to 150 mg twice daily Cmax: ↑ 97% during co-administration with Kaletra Due to CYP3A inhibition by 400/100 mg twice daily. lopinavir/ritonavir. Integrase inhibitor Raltegravir Raltegravir: No dose adjustment necessary AUC: ↔ Cmax: ↔ C12: ↓ 30% Lopinavir: ↔ Co-administration with other HIV protease inhibitors (PIs) According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended. Fosamprenavir/ Fosamprenavir: Co-administration of increased doses ritonavir (700/100 mg Amprenavir concentrations are of fosamprenavir (1400 mg BID) BID) significantly reduced. with Kaletra oral solution (533/133 mg BID) to protease inhibitor-experienced patients

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) maraviroc (HOS-086186) amprenavir (HOS-086183) raltegravir (HOS-086187) fosamprenavir (HOS-086182)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage f782d1ab1c57001581096637b1440b57b3cb9dd3d00bfd730e7f8085e3a57bae · Zeichen 5188–6569 im Abschnitt

Wechselwirkungen · Kaletra

Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 48–49

HOS-109005 · Präparat HOS-093083

48 (Lopinavir/ritonavir resulted in a higher incidence of 400/100 mg BID) gastrointestinal adverse events and elevations in triglycerides with the or combination regimen without increases in virological efficacy, Fosamprenavir when compared with standard doses (1400 mg BID) of fosamprenavir/ritonavir. Concomitant administration of these (Lopinavir/ritonavir medicinal products is not 533/133 mg BID) recommended. Kaletra must not be administered once daily in combination with amprenavir. Tipranavir/ritonavir Lopinavir: Concomitant administration of these (500/100 mg BID) AUC: ↓ 55% medicinal products is not Cmin: ↓ 70% recommended. Cmax: ↓ 47% Acid reducing agents Omeprazole (40 mg Omeprazole: ↔ No dose adjustment necessary QD) Lopinavir: ↔ Ranitidine (150 mg Ranitidine: ↔ No dose adjustment necessary single dose) Alpha1 adrenoreceptor antagonist Alfuzosin Alfuzosin: Concomitant administration of Due to CYP3A inhibition by Kaletra and alfuzosin is contra- lopinavir/ritonavir, concentrations indicated (see section 4.3) as of alfuzosin are expected to alfuzosin-related toxicity, including increase. hypotension, may be increased. Analgesics Fentanyl Fentanyl: Careful monitoring of adverse effects Increased risk of side-effects (notably respiratory depression but (respiratory depression, sedation) also sedation) is recommended when due to higher plasma fentanyl is concomitantly concentrations because of administered with Kaletra. CYP3A4 inhibition by lopinavir/ritonavir. Antianginal Ranolazine Due to CYP3A inhibition by The concomitant administration of lopinavir/ritonavir, concentrations Kaletra and ranolazine is of ranolazine are expected to contraindicated (see section 4.3). increase.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) amprenavir (HOS-086183) ranitidine (HOS-085660) fentanyl (HOS-086196) fosamprenavir (HOS-086182) ranolazine (HOS-086141) tipranavir (HOS-086184) omeprazole (HOS-085912)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 36be30eaedda7aebc321ed321c96a33a8b5f0e47dfdc414ad4d6358ff3954c0c · Zeichen 6614–9803 im Abschnitt

Wechselwirkungen · Kaletra

Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 83–84

HOS-109078 · Präparat HOS-093083

83 Maraviroc Maraviroc: The dose of maraviroc should be AUC: ↑ 295% decreased to 150 mg twice daily Cmax: ↑ 97% during co-administration with Due to CYP3A inhibition by Kaletra 400/100 mg twice daily. lopinavir/ritonavir. Integrase inhibitor Raltegravir Raltegravir: No dose adjustment necessary AUC: ↔ Cmax: ↔ C12: ↓ 30% Lopinavir: ↔ Co-administration with other HIV protease inhibitors (PIs) According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended. Fosamprenavir/ Fosamprenavir: Co-administration of increased ritonavir (700/100 mg Amprenavir concentrations are doses of fosamprenavir (1400 mg BID) significantly reduced. BID) with Kaletra oral solution (533/133 mg BID) to protease (Lopinavir/ritonavir inhibitor-experienced patients 400/100 mg BID) resulted in a higher incidence of gastrointestinal adverse events and or elevations in triglycerides with the combination regimen without Fosamprenavir increases in virological efficacy, (1400 mg BID) when compared with standard doses of fosamprenavir/ritonavir. (Lopinavir/ritonavir Concomitant administration of these 533/133 mg BID) medicinal products is not recommended. Kaletra must not be administered once daily in combination with amprenavir. Tipranavir/ritonavir Lopinavir: Concomitant administration of these (500/100 mg BID) AUC: ↓ 55% medicinal products is not Cmin: ↓ 70% recommended. Cmax: ↓ 47% Acid reducing agents Omeprazole (40 mg Omeprazole: ↔ No dose adjustment necessary QD) Lopinavir: ↔ Ranitidine (150 mg Ranitidine: ↔ No dose adjustment necessary single dose) Alpha1 adrenoreceptor antagonist Alfuzosin Alfuzosin: Concomitant administration of Due to CYP3A inhibition by Kaletra and alfuzosin is contra- lopinavir/ritonavir, concentrations indicated (see section 4.3) as of alfuzosin are expected to alfuzosin-related toxicity, including increase. hypotension, may be increased.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) protease (HOS-085623) maraviroc (HOS-086186) amprenavir (HOS-086183) ranitidine (HOS-085660) raltegravir (HOS-086187) fosamprenavir (HOS-086182) tipranavir (HOS-086184) omeprazole (HOS-085912)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 262bfc7747e8af6a0bc31322576cc9f33731bdf23847197000d08285e923bde2 · Zeichen 5337–8975 im Abschnitt

Wechselwirkungen · Vfend

VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13

HOS-109463 · Präparat HOS-093201

Low dose (100 mg BID)* Ritonavir Cmax  25% Coadministration of voriconazole Ritonavir AUC 13% and low-dose ritonavir (100 mg Voriconazole Cmax  24% BID) should be avoided unless an assessment of the benefit/risk Voriconazole AUC  39% to the patient justifies the use of voriconazole. Other HIV Protease Inhibitors Not studied clinically. In vitro Careful monitoring for any (including but not limited to: studies show that voriconazole may occurrence of drug toxicity saquinavir, amprenavir and inhibit the metabolism of HIV and/or lack of efficacy, and dose nelfinavir)* protease inhibitors and the adjustment may be needed. [CYP3A4 substrates and metabolism of voriconazole may inhibitors] also be inhibited by HIV protease inhibitors.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nelfinavir (HOS-084520) protease (HOS-085623) saquinavir (HOS-084522) amprenavir (HOS-086183) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 81b452654b014e91adf502a06508cfe5e46ea829e59260fa77bcc7896d35f33b · Zeichen 15356–16561 im Abschnitt

Wechselwirkungen · Vfend

VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 45

HOS-109542 · Präparat HOS-093201

Low dose (100 mg BID)* Ritonavir Cmax  25% Coadministration of voriconazole Ritonavir AUC 13% and low-dose ritonavir (100 mg Voriconazole Cmax  24% BID) should be avoided unless an assessment of the benefit/risk Voriconazole AUC  39% to the patient justifies the use of voriconazole. Other HIV Protease Inhibitors Not studied clinically. In vitro Careful monitoring for any (including but not limited to: studies show that voriconazole may occurrence of drug toxicity saquinavir, amprenavir and inhibit the metabolism of HIV and/or lack of efficacy, and dose nelfinavir)* protease inhibitors and the adjustment may be needed. [CYP3A4 substrates and metabolism of voriconazole may inhibitors] also be inhibited by HIV protease inhibitors. Efavirenz (a non-nucleoside reverse transcriptase inhibitor, (NNRTI)) [CYP450 inducer; CYP3A4 inhibitor and substrate] Efavirenz Cmax  38% Use of standard doses of Efavirenz 400 mg QD, Efavirenz AUC  44% voriconazole with efavirenz coadministered with Voriconazole Cmax  61% doses of 400 mg QD or higher is voriconazole 200 mg BID* Voriconazole AUC  77% contraindicated (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nelfinavir (HOS-084520) protease (HOS-085623) saquinavir (HOS-084522) amprenavir (HOS-086183) efavirenz (HOS-087947) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 0f766ad319d00482dae4f7644313c8278be71bfe0e23dffa63c5e8445c8c01eb · Zeichen 15763–17590 im Abschnitt

Wechselwirkungen · Vfend

VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 77

HOS-109606 · Präparat HOS-093201

Low dose (100 mg BID)* Ritonavir Cmax  25% Coadministration of voriconazole Ritonavir AUC 13% and low-dose ritonavir (100 mg Voriconazole Cmax  24% BID) should be avoided unless an assessment of the benefit/risk Voriconazole AUC  39% to the patient justifies the use of voriconazole. Other HIV Protease Inhibitors Not studied clinically. In vitro Careful monitoring for any (including but not limited to: studies show that voriconazole may occurrence of drug toxicity saquinavir, amprenavir and inhibit the metabolism of HIV and/or lack of efficacy, and dose nelfinavir)* protease inhibitors and the adjustment may be needed. [CYP3A4 substrates and metabolism of voriconazole may inhibitors] also be inhibited by HIV protease inhibitors.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nelfinavir (HOS-084520) protease (HOS-085623) saquinavir (HOS-084522) amprenavir (HOS-086183) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 81b452654b014e91adf502a06508cfe5e46ea829e59260fa77bcc7896d35f33b · Zeichen 15388–16593 im Abschnitt

Wechselwirkungen · Aptivus

Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 11

HOS-114814 · Präparat HOS-094169

Concomitant use of Aptivus/ritonavir caused a decrease of etravirine exposure that could significantly impair the virologic response to etravirine. Nevirapine The limited data available from a No dosage adjustment necessary. No interaction study phase IIa study in HIV-infected performed patients suggest that no significant interaction is expected between nevirapine and TPV/r. Moreover a study with TPV/r and another NNRTI (efavirenz) did not show any clinically relevant interaction (see above). Rilpivirine Concomitant use of rilpivirine Close monitoring for signs of No interaction study with some ritonavir-boosted rilpivirine toxicity and possibly performed protease inhibitors has also dose adjustment of rilpivirine demonstrated an increase in the is recommended when co- plasma concentrations of administered with rilpivirine. Aptivus/ritonavir. Protease inhibitors (PIs) According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended Amprenavir/ritonavir Amprenavir Cmax ↓ 39% The concomitant use of Aptivus, 600/100 mg BID Amprenavir AUC ↓ 44% co-administered with low dose Amprenavir Cmin ↓ 55% ritonavir, with amprenavir/ritonavir is not The clinical relevance of this recommended. reduction in amprenavir If the combination is nevertheless concentrations has not been considered necessary, a established. monitoring of the plasma levels of amprenavir is strongly Mechanism unknown. encouraged (see section 4.4). Atazanavir/ritonavir Atazanavir Cmax ↓ 57% The concomitant use of Aptivus, 300/100 mg QD Atazanavir AUC ↓ 68% co-administered with low dose (TPV/r 500/100 mg BID) Atazanavir Cmin ↓ 81% ritonavir, with atazanavir/ritonavir is not Mechanism unknown. recommended. If the co-administration is Tipranavir Cmax  8% nevertheless considered Tipranavir AUC  20% necessary, a close monitoring of Tipranavir Cmin  75% the safety of tipranavir and a monitoring of plasma Inhibition of CYP 3A4 by concentrations of atazanavir are atazanavir/ritonavir and strongly encouraged (see induction by tipranavir/r. section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) protease (HOS-085623) etravirine (HOS-088088) amprenavir (HOS-086183) rilpivirine (HOS-088090) efavirenz (HOS-087947) nevirapine (HOS-088064) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 0f93136f565c07762f6fd595573f7b2523cf9549d537511b9eb823e270e5cf53 · Zeichen 9065–12757 im Abschnitt

Wechselwirkungen · Prezista

PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 24–25

HOS-116434 · Präparat HOS-094447

24 # Studies have been performed at lower than recommended doses of darunavir or with a different dosing regimen (see section 4.2 Posology). † The efficacy and safety of the use of PREZISTA with 100 mg ritonavir and any other HIV PI (e.g. (fos)amprenavir and tipranavir) has not been established in HIV patients. According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended. ‡ Study was conducted with tenofovir disoproxil fumarate 300 mg once daily.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) amprenavir (HOS-086183) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521) tipranavir (HOS-086184)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 39b639411a5674b9266d293c1fa28c7bc34f2a852f4629bb2b419a20505f595a · Zeichen 78543–79082 im Abschnitt

Wechselwirkungen · Prezista

PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 66–67

HOS-116535 · Präparat HOS-094447

66 UROLOGICAL DRUGS Fesoterodine Not studied. Use with caution. Monitor for Solifenacin fesoterodine or solifenacin adverse reactions, dose reduction of fesoterodine or solifenacin may be necessary. # Studies have been performed at lower than recommended doses of darunavir or with a different dosing regimen (see section 4.2 Posology). † The efficacy and safety of the use of PREZISTA with 100 mg ritonavir and any other HIV PI (e.g. (fos)amprenavir and tipranavir) has not been established in HIV patients. According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended. ‡ Study was conducted with tenofovir disoproxil fumarate 300 mg once daily.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): solifenacin (HOS-116433) protease (HOS-085623) amprenavir (HOS-086183) fesoterodine (HOS-116432) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521) tipranavir (HOS-086184)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 4a138fc9e1c788e1d7747ba233c9254854c8390d924be8b5ea4eacff3a14e676 · Zeichen 69769–70897 im Abschnitt

Wechselwirkungen · Prezista

PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 106

HOS-116623 · Präparat HOS-094447

Midazolam (oral) Boosted PREZISTA with Triazolam triazolam or oral midazolam is contraindicated (see section 4.3). TREATMENT FOR PREMATURE EJACULATION Dapoxetine Not studied. Co-administration of boosted PREZISTA with dapoxetine is contraindicated. UROLOGICAL DRUGS Fesoterodine Not studied. Use with caution. Monitor for Solifenacin fesoterodine or solifenacin adverse reactions, dose reduction of fesoterodine or solifenacin may be necessary. # Studies have been performed at lower than recommended doses of darunavir or with a different dosing regimen (see section 4.2 Posology). † The efficacy and safety of the use of PREZISTA with 100 mg ritonavir and any other HIV PI (e.g. (fos)amprenavir and tipranavir) has not been established in HIV patients. According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended. ‡ Study was conducted with tenofovir disoproxil fumarate 300 mg once daily.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): solifenacin (HOS-116433) protease (HOS-085623) amprenavir (HOS-086183) fesoterodine (HOS-116432) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521) triazolam (HOS-086168) tipranavir (HOS-086184) midazolam (HOS-086167)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 14ad7ec122e17b6bf0a9b5a35c80cb2b9d577809d7de8d4ecda9d9afbe9bbd5b · Zeichen 77338–79172 im Abschnitt

Wechselwirkungen · Celsentri

CELSENTRI 150 mg film-coated tablets CELSENTRI 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10

HOS-118462 · Präparat HOS-094825

Fosamprenavir/ritonavir Maraviroc AUC12: ↑ 2.49 Concomitant use is not 700 mg/100 mg BID Maraviroc Cmax: ↑ 1.52 recommended. Significant (maraviroc 300 mg BID) Maraviroc C12: ↑ 4.74 reductions in amprenavir Cmin observed may result Amprenavir AUC12: ↓ 0.65 in virological failure in Amprenavir Cmax: ↓ 0.66 patients Amprenavir C12: ↓ 0.64

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amprenavir (HOS-086183) fosamprenavir (HOS-086182) ritonavir (HOS-084521)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-01-12T15:51:00Z · SHA-256 af7f0c7bbfd6e612d5a885c59ba9795f11ee85b00c3e0504de2a206af5fbec72 · Passage 1db1f8ce99132149e5de7ca4def48df5a8c75d3e98f57af9b3690710f0048433 · Zeichen 11233–11810 im Abschnitt

Quellenpassagen (52)

Wechselwirkungen · Norvir

Wechselwirkungen · Norvir

Wechselwirkungen · Viramune

Wechselwirkungen · Viramune

Wechselwirkungen · Viramune

Wechselwirkungen · Viramune

Wechselwirkungen · Viramune

Wechselwirkungen · Viramune

Wechselwirkungen · Kaletra

Wechselwirkungen · Kaletra

Wechselwirkungen · Kaletra

Wechselwirkungen · Kaletra

Wechselwirkungen · Vfend

Wechselwirkungen · Vfend

Wechselwirkungen · Vfend

Wechselwirkungen · Aptivus

Wechselwirkungen · Prezista

Wechselwirkungen · Prezista

Wechselwirkungen · Prezista

Wechselwirkungen · Celsentri